Nr.
Nume Status
Crt.
1
Endocrine Therapy With
or Without Abemaciclib Activ, inca nu
(LY2835219) Following
Surgery in Participants
With Breast Cancer
(monarchE)
2 Study of Nivolumab
Versus Placebo in
Participants With High-
Risk Breast Cancer
(CheckMate 7FL)
3 Study Assessing the Activ, inca nu
Efficacy and Safety of
Alpelisib Plus Fulvestrant
in Men and
Postmenopausal Women
With Advanced Breast
Cancer Which Progressed
on or After Aromatase
Inhibitor Treatment.
Locatie
Centrul de Oncologie Sf. Nectarie SRL
Craiova, Dolj, Romania, 200347
S.C. R.T.C. Radiology Therapeutic Center S.R.L.
Otopeni, Ilfov, Romania, 075100
SC Oncopremium Team SRL
recruteaza Baia Mare, Maramureș, Romania, 430291
Institutul Oncologic Dr TrestioreanuBucuresti
Bucuresti, Sector 2, Romania, 022328
Spitalul Clinic Filantropia
Bucuresti, Romania, 011171
Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj-Napoca
Cluj-Napoca, Romania, 400015
Spitalul Clinic Judetean de UrgentaSf.Apostol Andrei Constanta
Constanta, Romania, 900591
Local Institution Not yet recruiting
Bucharest, Romania, 011171
In curs de Contact: Site 0029
recrutare Local Institution Not yet recruiting
Bucuresti, Romania, 022328
Contact: Site 0025
Local Institution Not yet recruiting
Craiova, Romania, 200347
Contact: Site 0028
Local Institution Not yet recruiting
Floresti, Romania, 407280
Contact: Site 0027
Local Institution Not yet recruiting
Suceava, Romania, 720237
Contact: Site 0026
Novartis Investigative Site
recruteaza Floresti, Cluj, Romania, 407280
Novartis Investigative Site
Bucuresti, Romania, 011171
Novartis Investigative Site
Bucuresti, Romania, 030463
Novartis Investigative Site
Craiova, Romania, 200347
 (SOLAR-1)
4 A European Registry Activ, inca nu
Study to Prospectively recruteaza
Observe Treatment
Patterns and Outcomes in
Participants With Human
Epidermal Growth Factor
Receptor 2 (HER2)-
Positive Unresectable
Locally Advanced (LA) or
Metastatic Breast Cancer
(mBC) (SAMANTHA)
5 A Phase 3 Randomized, Activ, inca nu
Placebo-controlled Trial recruteaza
of Carboplatin and
Paclitaxel With or
Without Veliparib (ABT-
888) in HER2-negative
Metastatic or Locally
Advanced Unresectable
BRCA-associated Breast
Cancer
6 A Study Of Ipatasertib in
Combination With
Atezolizumab and In curs de
Paclitaxel as a Treatment recrutare
for Participants With
Locally Advanced or
Metastatic Triple-
Negative Breast Cancer.
7 A Randomized Study of Activ, inca nu
AZD2014 in Combination recruteaza
With Fulvestrant in
Metastatic or Advanced
Breast Cancer
8 A Study of Trastuzumab Activ, inca nu
Emtansine (Kadcyla) Plus recruteaza
Novartis Investigative Site
Iasi, Romania, 700483
Novartis Investigative Site
Timisoara, Romania, 300219
County Hospital Alba; Oncology
Alba Iulia, Romania, 510073
"Filantropia" Clinical Hospital; Gynecological Oncology
Bucharest, Romania, 011191
Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti
Bucuresti, Romania, 022328
Prof. Dr. I. Chiricuta Institute of Oncology
Cluj Napoca, Romania, 400015
Cluj-Napoca Emergency Clinical County Hospital; Medical Oncology
Cluj-Napoca, Romania, 400006
Centrul de OncologieSfantulNectarie
Craiova, Romania, 200347
Oncomed SRL
Timisoara, Romania, 300239
S.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 124948
Craiova, Dolj, Romania, 200347
lnstitutul Oncologic Trestiore /ID# 124943
Bucharest, Romania, 022328
Spitalul Clinic Judetean de Urgenta /ID# 124945
Cluj, Romania, 400006
Oncomed SRL /ID# 127598
Timisoara, Romania, 300239
"Filantropia" Clinical Hospital; Gynecological Oncology Not yet recruiting
Bucharest, Romania, 011191
Institute of Oncology "Prof. Dr. I. Chiricuta" Not yet recruiting
Cluj-Napoca, Romania, 400015
Oncology Center Sf. Nectarie Not yet recruiting
Craiova, Romania, 200347
Centrul de OncologieOncohelp Not yet recruiting
Timisoara, Romania, 300239
Center of Oncology Euroclinic
Bucharest, Romania
Oncology Center Sf Nectarie
Caracal, Romania
Cluj County Clinical Emergency Hospital, Clinical Department of Medical Oncology
Cluj-Napoca, Romania
Oncology Institute "Prof. Dr. Ion Chiricuta"
Cluj-Napoca, Romania
Oncology Center Oncolab Craiova
Craiova, Romania
Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti
Bucuresti, Romania, 022328
 Pertuzumab (Perjeta) Prof. Dr. I. Chiricuta Institute of Oncology
Following Anthracyclines Cluj Napoca, Romania, 400015
in Comparison With Cluj Clinical County Hospital; Oncology Dept
Trastuzumab (Herceptin) Cluj-Napoca, Romania, 400006
Plus Pertuzumab and a Regional Institute of Oncology Iasi
Taxane Following Iasi, Romania, 700483
Anthracyclines as
Adjuvant Therapy in
Participants With
Operable HER2-Positive
Primary Breast Cancer
9 A Study of Pertuzumab in Activ, inca nu Emergency University Bucharest Hospital; Oncology Department
Addition to recruteaza Bucharest, Romania, 050098
Chemotherapy and Prof. Dr. I. Chiricuta Institute of Oncology
Trastuzumab as Adjuvant Cluj Napoca, Romania, 400015
Therapy in Participants Oncology Inst. Cluj-Napoca; Cancer Dept
With Human Epidermal Cluj-Napoca, Romania, 400015
Growth Receptor 2 Euroclinic Center of Oncology SRL
(HER2)-Positive Primary Iasi, Romania, 700106
Breast Cancer
10 A Global Study to Activ, inca nu Research Site
Compare the Effects of recruteaza Braila, Romania, 810325
Fulvestrant and Arimidex Research Site
in a Subset of Patients Craiova, Romania, 200347
With Breast Cancer. Research Site
Onesti, Romania, 601048
Research Site
Timisoara, Romania, 300239
11 A Study Comparing In curs de "Filantropia" Clinical Hospital; Gynecological Oncology
Atezolizumab (Anti PD-L1 recrutare Bucharest, Romania, 011191
Antibody) In Combination
Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti
With Adjuvant
Bucuresti, Romania, 022328
Anthracycline/Taxane-
Based Chemotherapy Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; OncologieMedicala
Versus Chemotherapy Cluj Napoca, Romania, 400015
Alone In Patients With Centrul de OncologieSfantulNectarie
Operable Triple-Negative Craiova, Romania, 200347
Breast Cancer
12 Palbociclib (PD-0332991) Activ, inca nu Spitalul Clinic CF nr.2 Bucuresti
Combined With recruteaza Bucharest, Romania, 011464
Fulvestrant In Hormone Spitalul Municipal Ploiesti
Receptor+ HER2-Negative Ploiesti, Romania, 100337
Metastatic Breast Cancer SpitalulJudetean de Urgente "Sf. IoancelNou"
After Endocrine Failure Suceava, Romania, 720237
(PALOMA-3) Spitalul Clinic JudeteanMures
TgMures, Romania, 540142
13 A Study of Taselisib + Activ, inca nu Institut of Oncology Al. Trestioreanu Bucharest; Oncology Department
Fulvestrant Versus recruteaza Bucuresti, Romania, 022328
 Placebo + Fulvestrant in Prof. Dr. I. Chiricuta Institute of Oncology
Participants With Cluj Napoca, Romania, 400015
Advanced or Metastatic Oncology Center Sf. Nectarie
Breast Cancer Who Have Craiova, Romania, 200347
Disease Recurrence or Euroclinic Center of Oncology SRL
Progression During or Iasi, Romania, 700106
After Aromatase Inhibitor
Therapy
14 PAKT: AZD5363 in Activ, inca nu Prof. Dr. I. Chiricuta Oncology Institute
Combination With recruteaza Cluj-Napoca, Romania
Paclitaxel in Triple- Sf. Nectarie SRL Oncologie Medical Center
Negative Advanced or Craiova, Romania
Metastatic Breast Cancer Center of Oncology Euroclinic
Iași, Romania
15 A Study of Atezolizumab Activ, inca nu Prof. Dr. I. Chiricuta Institute of Oncology Active, not recruiting
and Paclitaxel Versus recruteaza Cluj Napoca, Romania, 400015
Placebo and Paclitaxel in
Participants With
Previously Untreated Centrul de OncologieSfantulNectarie
Locally Advanced or Craiova, Romania, 200347 Active, not recruiting
Metastatic Triple
Negative Breast Cancer
(TNBC)
16 Assessment of the Activ, inca nu Research Site
Efficacy and Safety of recruteaza Bucharest, Romania, 013811
Olaparib Monotherapy Research Site
Versus Physicians Choice Bucuresti, Romania, 011171
Chemotherapy in the Research Site
Treatment of Metastatic Bucuresti, Romania, 030171
Breast Cancer Patients Research Site
With Germline BRCA1/2 Cluj Napoca, Romania, 400015
Mutations. Research Site
Cluj-Napoca, Romania, 400015
17 A Study of Abemaciclib Activ, inca nu For additional information regarding investigative sites for this trial, contact 1-877-
CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern
(LY2835219) Combined recruteaza Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
With Fulvestrant in
Women With Hormone
Receptor Positive HER2
Negative Breast Cancer
18 A Study to Compare the Activ, inca nu Novartis Investigative Site
Safety and Efficacy of an recruteaza Bucharest, Romania, 050098
Aromatase Inhibitor in Novartis Investigative Site
Combination With Bucuresti, Romania, 022328
Lapatinib, Trastuzumab Novartis Investigative Site
or Both for the Treatment Timisoara, Romania, 300239
of Hormone Receptor
Positive, HER2+
Metastatic Breast Cancer
19 ALTTO (Adjuvant Activ, inca nu Novartis Investigative Site
Lapatinib And/Or recruteaza Bucharest, Romania, 022328
Trastuzumab Treatment Novartis Investigative Site
Optimisation) Study; BIG Bucharest, Romania, 050098
2-06/N063D Novartis Investigative Site
Bucuresti, Romania, 022328
Novartis Investigative Site
Cluj-Napoca, Romania, 400015
Novartis Investigative Site
Iasi, Romania, 700106
20 A Study of Cobimetinib Activ, inca nu Prof. Dr. I. Chiricuta Institute of Oncology
Plus Paclitaxel, recruteaza Cluj Napoca, Romania, 400015
Cobimetinib Plus Oncology Center Sf. Nectarie
Atezolizumab Plus Craiova, Romania, 200347
Paclitaxel, or Cobimetinib
Plus Atezolizumab Plus
Nab-Paclitaxel as Initial
Treatment for
Participants With Triple-
Negative Breast Cancer
That Has Spread
21 A Study of Atezolizumab Activ, inca nu Oncomed SRL
in Combination With recruteaza Timisoara, Romania, 300239
Nab-Paclitaxel Compared
With Placebo With Nab-
Paclitaxel for Participants
With Previously
Untreated Metastatic
Triple-Negative Breast
Cancer (IMpassion130)
22 A Trial to Evaluate In curs de Novartis Investigative Site
Craiova, Dolj, Romania, 200347
Efficacy and Safety of recrutare
Ribociclib With Endocrine Novartis Investigative Site
Therapy as Adjuvant Craiova, Dolj, Romania, 200535
Treatment in Patients Novartis Investigative Site
Bucuresti, Romania, 010991
With HR+/HER2- Early
Breast Cancer (NATALEE) Novartis Investigative Site
Bucuresti, Romania, 011171

Novartis Investigative Site

Cluj-Napoca, Romania, 400124

Novartis Investigative Site

Iasi, Romania, 700106

Novartis Investigative Site

23 A Study of Trastuzumab
Deruxtecan (T-DXd)
Versus Trastuzumab
Timisoara, Romania, 300239
Inca nu Institutul Oncologic Prof. Dr. Ion Chiricuta
Cluj-Napoca, Cluj, Romania, 400015
recruteaza Contact: Principal Investigator
 Emtansine (T-DM1) in
High-risk HER2-positive
Participants With
Residual Invasive Breast
Cancer Following
Neoadjuvant Therapy
(DESTINY-Breast05)
24 Study of Romiplostim for In curs de
Chemotherapy-induced recrutare
Thrombocytopenia in
Adult Subjects With Non-
small Cell Lung Cancer
(NSCLC), Ovarian Cancer,
or Breast Cancer
Onco Clinic Consult SA
Craiova, Dolj, Romania, 200103
Contact: Principal Investigator
Centrul de Oncologie Sfantu Nectarie
Craiova, Dolj, Romania, 200347
Contact: Principal Investigator
Institutul Oncologic Bucuresti IOB
Bucharest, Romania, 22328
Contact: Principal Investigator
Research Site Recruiting
Bucharest, Romania, 022328
Research Site Recruiting
Bucharest, Romania, 022338
Research Site Recruiting
Bucharest, Romania, 030171
Research Site Recruiting
Cluj Napoca, Romania, 400015
Research Site Recruiting
Iasi, Romania, 700483
Research Site Recruiting
Ploiesti, Romania, 100337
Research Site Recruiting
Timisoara, Romania, 300239